Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon

被引：1
|
作者：
Buse, JB
Rosenstock, J
机构：
[1] Univ N Carolina, Sch Med, Diabet Care Ctr, Div Endocrinol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Diabet Care Ctr, Div Gen Med, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Sch Med, Diabet Care Ctr, Div Clin Epidemiol, Chapel Hill, NC 27599 USA
[4] Dallas Diabet & Endocrine Ctr, Dallas, TX 75230 USA
[5] Univ Texas, SW Med Sch, Dallas, TX 75230 USA
来源：
CARDIOLOGY CLINICS | 2005年 / 23卷 / 02期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/j.ccl.2004.11.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This article focuses on the continuing clinical trials in patients who have diabetes mellitus and pre-diabetes mellitus in which cardiovascular disease outcomes-specifically, myocardial infarction, stroke, and cardiovascular death-are examined as primary outcomes.
引用
收藏
页码：211 / +
页数：11
相关论文
共 50 条
  • [1] Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon
    Buse, JB
    Rosenstock, J
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2005, 34 (01) : 221 - +
  • [2] Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
    Kapoor, Karan
    George, Praveen
    Miller, Michael
    [J]. CARDIOLOGY, 2016, 135 (02) : 108 - 126
  • [3] Trials of cardiovascular outcomes in diabetes mellitus
    Mannucci, Edoardo
    [J]. GIORNALE ITALIANO DI CARDIOLOGIA, 2014, 15 (12) : 27S - 31S
  • [4] MODELLING CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES IN THE ERA OF CARDIOVASCULAR OUTCOMES TRIALS
    McEwan, P.
    Chubb, B.
    Bennett, H.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A747 - A747
  • [5] Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus
    Vijayakumar, Shilpa
    Vaduganathan, Muthiah
    Butler, Javed
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2018, 16 (02) : 123 - 131
  • [6] Primary cardiovascular prevention with statins in type 2 diabetes mellitus
    Cuende, Jose I.
    [J]. MEDICINA CLINICA, 2015, 144 (09): : 431 - 432
  • [7] Cardiovascular disease prevention strategies for type 2 diabetes mellitus
    Katsiki, Niki
    Purrello, Francesco
    Tsioufis, Costas
    Mikhailidis, Dimitri P.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1243 - 1260
  • [8] Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    Scirica, Benjamin M.
    Bhatt, Deepak L.
    Braunwald, Eugene
    Steg, P. Gabriel
    Davidson, Jaime
    Hirshberg, Boaz
    Ohman, Peter
    Frederich, Robert
    Wiviott, Stephen D.
    Hoffman, Elaine B.
    Cavender, Matthew A.
    Udell, Jacob A.
    Desai, Nihar R.
    Mosenzon, Ofri
    McGuire, Darren K.
    Ray, Kausik K.
    Leiter, Lawrence A.
    Raz, Itamar
    Braunwald, Eugene
    Bhatt, Deepak L.
    Scirica, Benjamin M.
    Udell, Jacob A.
    Cavender, Matthew A.
    Desai, Nihar
    Abrahamsen, Timothy
    Grossman, Michelle
    Morin, Suzanne
    Im, Kyungah
    Hoffman, Elaine
    Gabovitch, Daniel
    Pricken, Alexandra
    Mosenzon, Ofri
    Buskila, Alona
    Ohman, Peter
    Hirshberg, Boaz
    Stahre, Christina
    Price, Deborah
    Billing-Clason, Solveig
    Sabel, Karin
    Monyak, John
    Sjostrand, Mikalea
    Wei, Cheryl
    Lu, Jane
    Miller, Elinor
    Raichlen, Joel
    Fitt, Sandy
    Frederich, Robert
    Iqbal, Nayyar
    Donovan, Mark
    Davidson, Jaime A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1317 - 1326
  • [9] Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus
    Jaeschke, Roman
    Gerstein, Hertzel
    [J]. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10): : 803 - 805
  • [10] Prevention of cardiovascular risk in patients with type 2 diabetes mellitus with aspirin
    Duly-Bouhanick, B
    Menard, S
    Hadjadj, S
    Soares-Barbosa, S
    Plun-Favreau, J
    Guilloteau, G
    [J]. PRESSE MEDICALE, 2001, 30 (02): : 87 - 91
12345